These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23523344)

  • 1. Governance of natural health products regulation: an iterative process.
    Walji R; Wiktorowicz M
    Health Policy; 2013 Jun; 111(1):86-94. PubMed ID: 23523344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives.
    Murty M
    Can J Physiol Pharmacol; 2007 Sep; 85(9):952-5. PubMed ID: 18066142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors.
    Laeeque H; Boon H; Kachan N; Cohen JC; D'Cruz J
    BMC Health Serv Res; 2006 May; 6():63. PubMed ID: 16734916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of natural health products in Canada.
    Smith A; Jogalekar S; Gibson A
    J Ethnopharmacol; 2014 Dec; 158 Pt B():507-10. PubMed ID: 24969823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance in Europe and North America: divergent approaches.
    Wiktorowicz M; Lexchin J; Moscou K
    Soc Sci Med; 2012 Jul; 75(1):165-70. PubMed ID: 22521677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory Oversight of Cell and Gene Therapy Products in Canada.
    Ridgway A; Agbanyo F; Wang J; Rosu-Myles M
    Adv Exp Med Biol; 2015; 871():49-71. PubMed ID: 26374212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future development of global regulations of Chinese herbal products.
    Fan TP; Deal G; Koo HL; Rees D; Sun H; Chen S; Dou JH; Makarov VG; Pozharitskaya ON; Shikov AN; Kim YS; Huang YT; Chang YS; Jia W; Dias A; Wong VC; Chan K
    J Ethnopharmacol; 2012 Apr; 140(3):568-86. PubMed ID: 22373513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reporting natural health product related adverse drug reactions: is it the pharmacist's responsibility?
    Walji R; Boon H; Barnes J; Welsh S; Austin Z; Baker GR
    Int J Pharm Pract; 2011 Dec; 19(6):383-91. PubMed ID: 22060233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herbal products in Canada. How safe are they?
    Kozyrskyj A
    Can Fam Physician; 1997 Apr; 43():697-702. PubMed ID: 9111986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural health product use in Canada: analysis of the National Population Health Survey.
    Singh SR; Levine MA
    Can J Clin Pharmacol; 2006; 13(2):e240-50. PubMed ID: 16921199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in natural health product research: The importance of standardization.
    Shan JJ; Rodgers K; Lai CT; Sutherland SK
    Proc West Pharmacol Soc; 2007; 50():24-30. PubMed ID: 18605225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Canadian federal methamphetamine precursor and essential chemical regulations on methamphetamine-related acute-care hospital admissions.
    Callaghan RC; Cunningham JK; Victor JC; Liu LM
    Drug Alcohol Depend; 2009 Dec; 105(3):185-93. PubMed ID: 19699042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An innovative model for regulating supplement products: natural health products in Canada.
    Nestmann ER; Harwood M; Martyres S
    Toxicology; 2006 Apr; 221(1):50-8. PubMed ID: 16472903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of US and Canadian precursor regulation on methamphetamine purity in the United States.
    Cunningham JK; Liu LM; Callaghan R
    Addiction; 2009 Mar; 104(3):441-53. PubMed ID: 19207353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.